Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3BNC117-duoCAR-T cells
- Development stage
- Preclinical
- Lead developer
- Albert Einstein College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
**3BNC117-duoCAR-T cells** are an investigational, genetically engineered anti-HIV cellular immunotherapy developed by Albert Einstein College of Medicine and Caring Cross. The product consists of T cells modified with lentiviral vectors to express a multispecific duoCAR directed against conserved epitopes of HIV-1 envelope glycoprotein gp120 and to secrete the broadly neutralizing anti-HIV antibody 3BNC117, which recognizes the gp120 CD4-binding site. The duoCAR component is intended to identify and cytotoxically eliminate HIV-infected cells, while secreted 3BNC117 neutralizes HIV-1 virions and may augment control of viral spread. Preclinical studies in vitro and in humanized mouse models showed greater suppression of plasma HIV RNA and tissue-associated HIV DNA than either 3BNC117-secreting T cells or duoCAR-T cells alone. The program is being investigated as a potential strategy for durable antiretroviral therapy-free remission of HIV-1 infection.
- Other names
- 3BNC-duoCAR-T cells3BNC117-secreting duoCAR-T cells
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on 3BNC117-duoCAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3BNC117-duoCAR-T cells.